W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzo

• Status: Completed
• Trial end date: 2010-06-12
• Target enrollment: 0
• Participant gender: All

Summary

This study was conducted to determine if the bioavailability of clindamycin and its metabolite clindamycin sulfoxide are altered by the concentration of BPO or the absence of methylparaben. This study compared the investigational study product and 2 marketed products:

• CLN 1%-BPO 3% Gel (clindamycin 1%-BPO 3%), methylparaben-free

• Topical Gel (clindamycin 1%-BPO 5%), methylparaben-preserved (Topical Gel-MP)

• Once Daily Gel ((clindamycin 1%-BPO 5%), methylparaben-free (Topical Gel-MPF)

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stiefel, a GSK Company
• Collaborator: GlaxoSmithKline
• Treatments: Benzoyl Peroxide; Clindamycin; Clindamycin palmitate; Clindamycin phosphate

Criteria

Inclusion Criteria:

• Capable of understanding and willing to provide signed and dated written voluntary informed consent (and HIPAA authorization) before any protocol-specific procedures were performed. Subjects under the legal age of consent in the state where the study was conducted must have provided assent and have had the written informed consent of a parent or guardian.

• Male or female 12 to 45 years of age at time of consent.

• Moderate-to-severe facial acne, defined as an ISGA score of 3 or greater.

• Able to complete the study and to comply with study instructions.

• Sexually-active females of childbearing potential participating in the study must have agreed to use a medically-acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential was defined as one who is biologically capable of becoming pregnant, including perimenopausal women who are less than 2 years from their last menses. Acceptable contraceptive methods included the following:

• Hormonal contraception, including oral, injectable, or implantable methods started at least 3 months prior to screening. If hormonal contraception was started less than 3 months prior to screening, then a form of nonhormonal contraception should have been added until the third continuous month of hormonal contraception had been completed.

• Two forms of reliable nonhormonal contraception, to include the use of either an intrauterine device plus a reliable barrier method or 2 reliable barrier methods. Reliable barrier methods include condoms or diaphragms. A cervical cap is also a reliable barrier method, provided the female subject has never given birth vaginally. The combined use of a condom and spermicide constitute 2 forms of acceptable nonhormonal contraception, provided that they are both used properly. The use of spermicide alone and the improper use of condoms are inferior methods of contraception. Subjects with surgical sterilization, including tubal sterilization or partner's vasectomy, must have used a form of nonhormonal contraception. A barrier method or sterilization plus spermicide was acceptable.

• Women who were not currently sexually active must have agreed to use a medically-acceptable method of contraception should they have become sexually active while participating in the study.

Exclusion Criteria:

• Female who was pregnant, trying to become pregnant, or breast feeding.

• Participation in any investigational study within 4 weeks of Day 1 or who were scheduled to participate in another investigational study in the next 2 weeks.

• Used prohibited medications within specified time period before Day 1.

• Currently using any medication that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.

• History or evidence of skin conditions other than acne (eg, eczema, rosacea, seborrheic dermatitis, birthmarks, tattoos) that would interfere with study evaluations.

• History or presence of regional enteritis or inflammatory bowel disease (eg, ulcerative colitis, pseudomembranous colitis, chronic diarrhea, celiac disease, Crohn's disease, or history of antibiotic-associated colitis) or similar symptoms.

• Had any major illness within 4 weeks of Day 1.

• Anticipated need for surgery or hospitalization during the study.

• Blood donation, or equivalent blood loss (~480 mL), within 3 months of Day 1.

• Anemia or any other systemic disease condition for which a loss of 120 mL of blood over a 1-week period may put the subject at undue risk.

• Considered immunocompromised.

• Currently suffering from any disease or condition that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.

• Current smoker or smoker with less than 4 weeks abstinence from smoking and nicotine-containing products.

• Anticipated need to engage in activities or exercise that would cause profuse sweating during the study.

• Required or desired excessive or prolonged exposure to ultraviolet light (eg, sunlight, or tanning beds) during the study.

• Clinically relevant history of or current evidence of abuse of alcohol or other drugs.

• History of known or suspected intolerance, hypersensitivity, or allergic reaction to any of the ingredients of the study products, including clindamycin and BPO.

• Considered unable or unlikely to attend the necessary visits.

• Lived in the same household as currently enrolled subjects.

• Employee of the investigator, clinical research organization, or Stiefel who was involved in the study, or an immediate family member (eg, partner, offspring, parents, siblings, or sibling's offspring) of an employee who was involved in the study.